Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13
Partnerships 14
Meiji Seika Pharma Enters into Agreement with Santen Pharma 14
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17
Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19
Licensing Agreements 20
Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22
Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23
Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24
Meiji Seika Pharma Enters into Licensing Agreement with MSD 25
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26
Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29
Acquisition 30
Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30
Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32
Meiji Seika Pharma Co Ltd – Key Competitors 33
Meiji Seika Pharma Co Ltd – Key Employees 34
Meiji Seika Pharma Co Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Joint Venture 36
Recent Developments 37
Corporate Communications 37
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 37
Product News 38
04/12/2018: Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology 38
Clinical Trials 39
Jun 05, 2018: Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018 39
Oct 20, 2017: Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advent International Rumored To Acquire 25% Stake In Medreich From Temasek 13
Meiji Seika Pharma Enters into Agreement with Santen Pharma 14
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 15
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 16
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 17
Meiji Seika Pharma Enters into Agreement with Ohki Pharma 18
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 19
Meiji Seika Pharma Receives Rights of Epadail S from Mochida Pharma 20
Spero Therapeutics Enters into Licensing Agreement with Meiji Seika Pharma 21
Eisai Enters into Licensing Agreement with Meiji Seika Pharma 22
Meiji Seika Pharma Enters into Licensing Agreement with Solasia Pharma for Episil 23
Solasia Pharma Enters into Licensing Agreement with Meiji Seika Pharma for Darinaparsin 24
Meiji Seika Pharma Enters into Licensing Agreement with MSD 25
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 26
Curadim Pharma Enters into Licensing Agreement with Meiji Seika Pharma 28
Roche Enters into Licensing Agreement with Meiji Seika Pharma and Fedora Pharma 29
Meiji Acquires 49% Stake in Kaketsuken for USD0.16 Billion 30
Meiji Seika Pharma Acquires Medreich Lifecare for USD290 Million 32
Meiji Seika Pharma Co Ltd, Key Competitors 33
Meiji Seika Pharma Co Ltd, Key Employees 34
Meiji Seika Pharma Co Ltd, Other Locations 35
Meiji Seika Pharma Co Ltd, Subsidiaries 35
Meiji Seika Pharma Co Ltd, Joint Venture 36
List of Figures
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Meiji Seika Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Meiji Seika Pharma Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer